A b s t r a c t
Cardiac troponins I and T have a central role in the diagnosis and management of patients with suspected acute coronary syndrome (ACS). [1] [2] [3] [4] The biochemical diagnosis of myocardial infarction (MI) is defined by troponin status. In addition, troponin provides valuable information for assessing the risk of recurrent ischemic events and for guiding therapeutic decisions. The analytic performance of troponin assays, in particular their sensitivity, has improved significantly since their initial clinical implementation. [5] [6] [7] The European Society of Cardiology (ESC) and the American College of Cardiology (ACC) jointly recommend using a diagnostic cut point at the 99th percentile of the reference population with an optimal coefficient of variation (CV) of less than or equal to 10%. 1 Thus, the threshold for myocardial injury has been continually redefined as assay performance has improved, in conjunction with data demonstrating important clinical implications of increased concentrations of troponin in patients with suspected ACS. 1, 2, [8] [9] [10] Current troponin testing has limitations, including antibody specificity, assay imprecision, lack of standardization, and the relatively late increase in the circulating troponin level after the onset of ischemia. Studies of first-and second-generation assays have shown lower diagnostic sensitivity of troponin when measured early (<6 hours) after symptom onset. [11] [12] [13] [14] As such, patients seeking care early in the course of the myocardial injury, so called early presenters, will often have undetectable levels of troponin on initial evaluation, but will later have a positive troponin result. Early presenters carry a similar or worse prognosis compared with patients who have detectable troponin levels at initial examination. 15 Given the central clinical goal of rapid triage for patients with chest pain syndromes and the potential benefits of early intervention, 16 this delay in a detectable rise in the troponin level has led to interest in its combined use with "early markers" of necrosis such as myoglobin or fatty acid binding protein. However, it is possible that improvements in the early sensitivity of troponin would obviate the need for additional, potentially duplicative, biomarkers of necrosis. 17 We thus evaluated the potential of a newly available more sensitive assay for troponin I (TnI-Ultra, Siemens Medical Solutions, Diagnostics Division, Tarrytown, NY) to improve early detection of myocardial injury in patients whose serial cardiac TnI (cTnI) testing revealed an initially negative cTnI result followed by a positive cTnI result in at least 1 of the subsequently collected specimens.
Materials and Methods
Approval for this study was acquired from Brigham and Women's Hospital (Boston, MA) Human Research Committee. By using our laboratory information system, we identified patients who initially had 1 or more negative cTnI (<0.10 ng/mL [0.10 µg/L]) specimens followed by 1 or more positive cTnI (≥0.10 ng/mL [0.10 µg/L]) results within 24 hours. We collected discarded plasma specimens from this cohort of patients, including the initially cTnI-and all subsequently cTnI+ and/or cTnI-samples drawn within 72 hours from the first cTnI test. Specimens were collected between November 2005 and May 2006 and stored at -70°C.
We currently perform the cTnI assay on the ADVIA Centaur analyzer (Siemens Medical Solutions). This assay for cTnI is a 3-site sandwich immunoassay using direct chemiluminescent technology with polyclonal and monoclonal TnI antibodies. The manufacturer states an assay range of 0.10 to 50 ng/mL (0.10-50 µg/L). The CV at 0.10 ng/mL (0.10 µg/L) ranges from 10% to 12% in our quarterly evaluations ❚Figure 1❚.
Consequently, we use a diagnostic cutoff of 0.10 ng/mL (0.10 µg/L), as recommended by the manufacturer. 18 The ADVIA Centaur TnI-Ultra assay is a 3-site sandwich immunoassay using direct chemiluminescent technology with 1 polyclonal antibody and 2 monoclonal antibodies directed against the stable, central region of the TnI molecule. These antibodies are configured to give maximum binding to each troponin molecule. An ancillary reagent is included to reduce nonspecific binding. The manufacturer states an assay range of 0.006-50 ng/mL (0.006-50 µg/L); however, the functional sensitivity at which the CV is 20% was determined to be 0.015 ng/mL (0.015 µg/L). A reference range study, conducted by the manufacturer, using 1,845 fresh samples (serum, EDTA, and lithium heparin plasma) from 648 apparently healthy people ranging from 17 to 91 years of age, demonstrated a 99th percentile of 0.04 ng/mL (0.04 µg/L). A total CV of 10% was obtained at a level of 0.03 ng/mL (0.03 µg/L). Consistent with the ESC/ACC recommendations, 1 we used the manufacturer's recommended diagnostic cut point of 0.04 ng/mL (0.04 µg/L; 99th percentile) for the TnI-Ultra assay. In addition, we verified the total imprecision using different reagent lots during multiple days by determining the CV at decreasing concentrations of TnI.
Stored specimens from all time points were assayed for both cTnI and TnI-Ultra assays according to the manufacturer's instructions by trained technologists who were blinded to previous results and patient history. Each patient's electronic medical record was reviewed, and clinical data were abstracted by an investigator (S.E.F.M.) blinded to the TnI-Ultra results to determine patient demographics and the principal clinical diagnosis.
Results
During the study period, 103 patients had a negative cTnI result followed by a positive cTnI result within 24 hours. A total of 356 serial specimens were analyzed for cTnI and TnIUltra. ❚Table 1❚ characterizes the study population, including average age, sex, and principal diagnoses. The diagnosis of ACS was based on the guidelines published by the ACC, which includes clinical symptoms, electrocardiographic changes, and/or a typical rise and fall in biochemical markers of necrosis. [1] [2] [3] The performance characteristics of TnI-Ultra were determined. By using the TnI-Ultra, a 10% CV was achieved at a concentration of 0.03 to 0.04 ng/mL (0.03-0.04 µg/L; Figure 1 ), whereas the cTnI assay has a 10% CV at 0.10 to 0.12 ng/mL (0.10-0.12 µg/L).
By design of this study, all baseline cTnI results using our current assay were less than the diagnostic decision limit. In contrast, TnI-Ultra was positive in the baseline specimens of 63 patients (61.2%) ❚Figure 2❚. The majority of patients did not have positive cTnI results until 9 to 10 hours after the baseline specimen was drawn. This usually represented the second specimen obtained. However, in 7 patients with suspected myocardial injury, more than 1 specimen was obtained between a positive TnI-Ultra result and a positive cTnI result. There were no specimens in which the TnI-Ultra results were negative and the standard cTnI result was positive. Overall, the TnI-Ultra result was positive (>0.04 ng/mL [0.04 µg/L]) before the cTnI result in 66 (64.1%) of 103 patients, allowing the diagnosis of myocardial injury to be made earlier. The difference in the 63 patients noted previously and the 66 patients overall can be explained by the fact that in 3 of the patients, the TnI-Ultra result was positive before the cTnI result but not on the baseline specimen. Most physicians in the study followed the ESC/ACC guidelines and obtained cTnI measurements at initial examination and 6 to 9 and 12 to 24 hours later. For this reason, an average of 564 minutes (9.4 hours) elapsed between a positive TnI-Ultra result and a positive cTnI result in this particular set of serial specimens. When restricted to a subset of patients with a principal diagnosis of ACS, the data were highly consistent with the overall results. Of 103 patients, 31 had initial symptoms suggestive of myocardial injury and were eventually diagnosed with ACS (Table 1 ). The biochemical diagnosis of myocardial injury would have been confirmed earlier by TnI-Ultra in 52% of these patients. Of the patients with ACS with the earlier rise in TnI-Ultra, only 5 (31%) had accompanying physical examination and/or electrocardiographic findings suggestive of ACS. ❚Figure 3❚ depicts 4 of the 31 patients with ACS and the evolution of their troponin concentrations over time. All patients had significant troponin elevations that were indicated earlier by TnI-Ultra. Because physicians usually waited at least 6 hours to obtain a subsequent troponin level, TnI-Ultra allowed the diagnosis of ACS to be made an average of 570 minutes (9.5 hours) earlier, consistent with the average delay of 9.4 hours in all patients studied.
Discussion
The first report of the use of cTnI for diagnosis of MI was published in 1987. 5, 19 Despite the advances in troponin assays since that time, [5] [6] [7] improvements are still needed in analytic performance, assay standardization, antibody specificity, and elimination of interference. It is highly probable that troponin will remain the "gold standard" for diagnosis of myocardial injury in the near future. Clinicians and scientists have advocated for better assays with improved clinical sensitivity and precision, and many manufacturers have or are developing new assays to meet these criteria; however, the clinical impact of such changes for diagnostic and prognostic applications needs careful assessment.
In this study, we evaluated the potential diagnostic advantage of one such assay, TnI-Ultra, and found that it is possible to significantly increase the number of patients with ACS and definitive myocardial injury who are detected at the time of initial examination compared with the use of our established assay. 18, 20 Because, in general, clinicians follow the recommendation to serially measure TnI at initial examination and 6 to 9 and 12 to 24 hours later, in our study population, we found that reporting TnI-Ultra results would allow the diagnosis of cardiac injury to be made an average of 9 hours sooner. Furthermore, in our laboratory, the TnI-Ultra assay provides a CV of 10% at concentrations between 0.03 and 0.04 ng/mL (0.03-0.04 µg/L). This result is consistent with recommendations to achieve this optimal CV at the level of the 99th percentile and illustrates improved analytic performance of the TnI-Ultra compared with the current cTnI assay.
It is important to note that the ability to provide earlier detection for more than 50% of patients who were subsequently confirmed to have ACS at initial examination has the potential to substantially enhance early triage in the emergency setting and provide clinicians the opportunity to begin appropriate therapy for high-risk patients as early as possible. A rise and/or fall in cardiac troponin levels together with clinical evidence of myocardial ischemia is required for the diagnosis of ACS. The combination of the enhanced sensitivity and precision of this more sensitive troponin assay should allow significant changes in troponin levels (ie, presence or absence of ACS) to be detected in shorter intervals than the 6-to 9-and 12-to 24-hour windows that are currently recommended. In the present era of demands that threaten to exceed resources in acute care, emergency physicians, in particular, place very high value on rapid turnaround of results that influence triage. 21 Thus, the ability to obtain a potentially treatment-defining result earlier is of clinical importance.
There are several limitations in our study. It is a retrospective study with a focused objective regarding the timing of detection of myocardial injury in patients with established cardiac injury. The study was not designed to evaluate prognosis, the impact of therapy, or diagnostic specificity (or negative predictive value) among patients with MI vs control subjects. In addition, patients with underlying diagnoses other than ACS were not excluded. Although troponins offer high tissue specificity and reflect irreversible myocardial necrosis, they do not indicate the mechanism of myocardial injury. [22] [23] [24] Many conditions other than ACS are associated with an increase in troponin levels, such as myocarditis, pulmonary embolism, acute heart failure, septic shock, and renal failure. 22, 23, 25, 26 Our results show that, as expected, myocardial injury will also be detected earlier in cases in which the mechanism of injury is not ACS. Additional studies to characterize diagnostic and prognostic performance in the broad population of patients with nontraumatic chest pain are likely to be useful. In addition, more frequently obtaining blood samples in the first several hours after initial examination would be needed to more accurately quantify the average time benefit of TnI-Ultra. From previous studies, we estimate that owing to its enhanced sensitivity, TnI-Ultra will detect injury at least 30 minutes earlier than cTnI. [27] [28] [29] We found that the new more sensitive assay for cTnI (TnI-Ultra) offers superior analytic performance and detects myocardial injury earlier than the present generation assay from the same manufacturer. Implementation of the newer assay is likely to facilitate earlier identification of and intervention in high-risk patients with ACS. 
